» Articles » PMID: 12824062

Amyloid Precursor Protein (APP) and the Biology of Proteolytic Processing: Relevance to Alzheimer's Disease

Overview
Publisher Elsevier
Date 2003 Jun 26
PMID 12824062
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

The processing of amyloid precursor protein (APP) generates amyloid-beta (Abeta) peptides 1-40 and 1-42. The latter is neurotoxic and its accumulation results in amyloid fibril formation and the generation of senile plaques, the hallmark of Alzheimer's disease (AD). Whilst there has been considerable progress made in understanding the generation of Abeta by alpha-, beta- and gamma-secretase activity on APP, recently enzymes involved in the degradation of Abeta have been identified including neprilysin and insulin-degrading enzyme (IDE). We review the pathways involved in proteolytic processing of APP and discuss the potential implications of aberrant proteolysis on neurodegeneration. It is conceivable that single nucleotide polymorphisms (SNPs) in the regulatory regions of genes in these proteolytic cascades, which alter their expression, could contribute to some of the age-related changes seen in AD.

Citing Articles

Diverse role of S100 calcium-binding protein B in alzheimer's disease: pathological mechanisms and therapeutic implications.

Sarkar S, Porel P, Kosey S, Aran K Inflammopharmacology. 2025; .

PMID: 40057929 DOI: 10.1007/s10787-025-01697-y.


Case report: Double mutations in a patient with early-onset Alzheimer's disease in China, PSEN2 and IDE variants.

Chang Z, Wang Z, Luo L, Xie Z, Yue C, Bian X Front Neurosci. 2024; 18:1423892.

PMID: 39539495 PMC: 11557526. DOI: 10.3389/fnins.2024.1423892.


Blockade of brain alkaline phosphatase efficiently reduces amyloid-β plaque burden and associated cognitive impairment.

Soria-Tobar L, Roman-Valero L, Sebastian-Serrano A, Aivar P, Alvarez-Castelao B, Diaz-Hernandez M Alzheimers Res Ther. 2024; 16(1):233.

PMID: 39438925 PMC: 11494749. DOI: 10.1186/s13195-024-01600-x.


Carotenoid Supplementation for Alleviating the Symptoms of Alzheimer's Disease.

Flieger J, Forma A, Flieger W, Flieger M, Gawlik P, Dzierzynski E Int J Mol Sci. 2024; 25(16).

PMID: 39201668 PMC: 11354426. DOI: 10.3390/ijms25168982.


ADME profiling, molecular docking, DFT, and MEP analysis reveal cissamaline, cissamanine, and cissamdine from L.f. as potential anti-Alzheimer's agents.

Alhawarri M, Al-Thiabat M, Dubey A, Tufail A, Fouad D, Alrimawi B RSC Adv. 2024; 14(14):9878-9891.

PMID: 38528929 PMC: 10961956. DOI: 10.1039/d4ra01070a.